Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia

Published:2015-01-08 Issue:2 Volume:125 Page:407-410
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lamothe Betty¹,Cervantes-Gomez Fabiola¹,Sivina Mariela²,Wierda William G.²,Keating Michael J.²,Gandhi Varsha³

Affiliation:

1. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3. Departments of Experimental Therapeutics and Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/2/407/1385362/407.pdf

Reference12 articles.

1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.;Honigberg;Proc Natl Acad Sci USA,2010

2. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

3. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.;O’Brien;Lancet Oncol,2014

4. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.;Herman;Leukemia,2014

5. Carfilzomib.;Kortuem;Blood,2013

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia;Cancer Research;2024-01-19

2. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy;npj Precision Oncology;2022-12-01

3. The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions;Cancers;2022-02-02

4. Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia;Journal of Leukocyte Biology;2021-07-20

5. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma;British Journal of Haematology;2020-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3